Patents by Inventor Valerie Azoulay
Valerie Azoulay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220031622Abstract: An omeprazole delayed release tablet comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide.Type: ApplicationFiled: October 14, 2021Publication date: February 3, 2022Applicant: DEXCEL PHARMA TECHNOLOGIES LTD.Inventors: Adel PENHASI, Avi Avramoff, Maxim Gomberg, Valerie Azoulay
-
Publication number: 20180271790Abstract: A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.Type: ApplicationFiled: October 4, 2017Publication date: September 27, 2018Applicant: Dexcel Pharma Technologies Ltd.Inventors: Adel PENHASI, Avi AVRAMOFF, Maxim GOMBERG, Valerie AZOULAY
-
Publication number: 20160113878Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.Type: ApplicationFiled: January 6, 2016Publication date: April 28, 2016Applicant: DEXCEL LTD.Inventors: Raffael Lahav, Valerie Azoulay
-
Patent number: 9023391Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.Type: GrantFiled: April 17, 2007Date of Patent: May 5, 2015Assignee: Dexcel Ltd.Inventors: Valerie Azoulay, Erica Lahav
-
Publication number: 20140178469Abstract: A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.Type: ApplicationFiled: October 15, 2013Publication date: June 26, 2014Applicant: DEXCEL PHARMA TECHNOLOGIES LTD.Inventors: Adel PENHASI, Avi AVRAMOFF, Maxim GOMBERG, Valerie AZOULAY
-
Publication number: 20120244219Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.Type: ApplicationFiled: April 26, 2012Publication date: September 27, 2012Inventors: RAFFAEL LAHAV, ERICA LAHAV, VALERIE AZOULAY
-
Publication number: 20110038933Abstract: A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.Type: ApplicationFiled: May 5, 2009Publication date: February 17, 2011Applicant: DEXCELL LTD.Inventors: Valerie Azoulay, Avi Avramoff, Adel Penhasi, Maxim Gomberg
-
Publication number: 20070196485Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.Type: ApplicationFiled: April 17, 2007Publication date: August 23, 2007Applicant: DEXCEL LTD.Inventors: Raffael Lahav, Erica Lahav, Valerie Azoulay
-
Patent number: 7255878Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.Type: GrantFiled: June 21, 2000Date of Patent: August 14, 2007Assignee: Dexcel Ltd.Inventors: Erica Lahav, legal representative, Valerie Azoulay, Raffael Lahav, deceased
-
Publication number: 20070065513Abstract: A stable composition comprising a substrate comprising lansoprazole (preferably in the base form), without any alkaline agent; a subcoating layer containing alkaline agent; and an enteric coating layer. The substrate is preferably an inert core with an active layer (containing lansoprazole) layered over it.Type: ApplicationFiled: November 1, 2004Publication date: March 22, 2007Inventors: Avi Avramoff, Valerie Azoulay